J I Silverberg1,2, D Lei2, M Yousaf2, S R Janmohamed2, P P Vakharia3, R Chopra4, R Chavda5, S Gabriel5, K R Patel6, V Singam7, R Kantor4, D Y Hsu8. 1. Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 2. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 3. Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. State University of New York Downstate Medical Center, Brooklyn, NY, USA. 5. Galderma SA, Rx Strategy & Innovation Group, La Tour-de-Peliz, Switzerland. 6. Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. 7. Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, USA. 8. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Abstract
BACKGROUND: Multiple clinician-reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice. OBJECTIVES: To determine the measurement properties of the product of validated Investigator's Global Assessment for AD (vIGA) and body surface area (BSA) overall or divided into six categories (cBSA: 0%/0.1, <10%/10, <30%/30, <50%/50, <70%/70 and <90%/90-100%) and compare with other clinician-reported and patient-reported outcomes in adults and children with AD. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 653). RESULTS: vIGA*BSA and vIGA*cBSA had good convergent validity with BSA (Spearman's ρ = 0.97 and 0.93), eczema area and severity index (ρ = 0.94 and 0.92), and objective SCORAD (ρ = 0.88 and 0.89); and weak-to-good convergent validity with Numeric Rating Scale average itch (ρ = 0.22 and 0.22) and worst itch (ρ = 0.27 and 0.28), Patient-Oriented Eczema Measure (ρ = 0.44 and 0.43), Dermatology Life Quality Index (ρ = 0.48 and 0.49), ItchyQOL (ρ = 0.45 and 0.46), PROMIS Sleep Disturbance (ρ = 0.46 and 0.37) and sleep-related impairment (ρ = 0.31 and 0.31) in adults and/or children; very good discriminant validity for physician-reported global AD severity; good responsiveness to change of severity of AD and itch; and good reliability (intraclass correlation coefficient [95% confidence interval]: 0.72 [0.60-0.81] and 0.74 [0.62-0.82]) with no floor or ceiling effects. Thresholds for interpretability bands and clinically important difference were established. CONCLUSIONS: vIGA*BSA and vIGA*cBSA scores showed good convergent and discriminant validity, reliability, responsiveness and interpretability in adults and children with AD, and were feasible for use in clinical practice. vIGA*BSA and vIGA*cBSA had slightly lower convergent validity than EASI or objective SCORAD, but might be more efficient to collect and score.
BACKGROUND: Multiple clinician-reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice. OBJECTIVES: To determine the measurement properties of the product of validated Investigator's Global Assessment for AD (vIGA) and body surface area (BSA) overall or divided into six categories (cBSA: 0%/0.1, <10%/10, <30%/30, <50%/50, <70%/70 and <90%/90-100%) and compare with other clinician-reported and patient-reported outcomes in adults and children with AD. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 653). RESULTS: vIGA*BSA and vIGA*cBSA had good convergent validity with BSA (Spearman's ρ = 0.97 and 0.93), eczema area and severity index (ρ = 0.94 and 0.92), and objective SCORAD (ρ = 0.88 and 0.89); and weak-to-good convergent validity with Numeric Rating Scale average itch (ρ = 0.22 and 0.22) and worst itch (ρ = 0.27 and 0.28), Patient-Oriented Eczema Measure (ρ = 0.44 and 0.43), Dermatology Life Quality Index (ρ = 0.48 and 0.49), ItchyQOL (ρ = 0.45 and 0.46), PROMIS Sleep Disturbance (ρ = 0.46 and 0.37) and sleep-related impairment (ρ = 0.31 and 0.31) in adults and/or children; very good discriminant validity for physician-reported global AD severity; good responsiveness to change of severity of AD and itch; and good reliability (intraclass correlation coefficient [95% confidence interval]: 0.72 [0.60-0.81] and 0.74 [0.62-0.82]) with no floor or ceiling effects. Thresholds for interpretability bands and clinically important difference were established. CONCLUSIONS: vIGA*BSA and vIGA*cBSA scores showed good convergent and discriminant validity, reliability, responsiveness and interpretability in adults and children with AD, and were feasible for use in clinical practice. vIGA*BSA and vIGA*cBSA had slightly lower convergent validity than EASI or objective SCORAD, but might be more efficient to collect and score.
Authors: Masaki Futamura; Yael A Leshem; Kim S Thomas; Helen Nankervis; Hywel C Williams; Eric L Simpson Journal: J Am Acad Dermatol Date: 2015-12-11 Impact factor: 11.527
Authors: D K Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Sacotte; K R Patel; V Singam; S Immaneni; R Kantor; D Y Hsu; J I Silverberg Journal: Br J Dermatol Date: 2020-03-05 Impact factor: 9.302
Authors: L A A Gerbens; C A C Prinsen; J R Chalmers; A M Drucker; L B von Kobyletzki; J Limpens; H Nankervis; Å Svensson; C B Terwee; J Zhang; C J Apfelbacher; P I Spuls Journal: Allergy Date: 2016-07-13 Impact factor: 13.146
Authors: A Wollenberg; S Barbarot; T Bieber; S Christen-Zaech; M Deleuran; A Fink-Wagner; U Gieler; G Girolomoni; S Lau; A Muraro; M Czarnecka-Operacz; T Schäfer; P Schmid-Grendelmeier; D Simon; Z Szalai; J C Szepietowski; A Taïeb; A Torrelo; T Werfel; J Ring Journal: J Eur Acad Dermatol Venereol Date: 2018-05 Impact factor: 6.166
Authors: Jochen Schmitt; Phyllis I Spuls; Kim S Thomas; Eric Simpson; Masutaka Furue; Stefanie Deckert; Magdalene Dohil; Christian Apfelbacher; Jasvinder A Singh; Joanne Chalmers; Hywel C Williams Journal: J Allergy Clin Immunol Date: 2014-10 Impact factor: 10.793
Authors: Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg Journal: J Invest Dermatol Date: 2021-08-02 Impact factor: 8.551